1 Proteomic profiling of peripheral blood mononuclear cells reveals immune dysregulation and metabolic alterations in kidney transplant recipients with 2 COVID-19 3 4 Giuseppe G. F. Leite^{1*}, Mônica Bragança Sousa¹, Larissa de Oliveira C. P. Rodrigues¹, 5 Milena Karina Colo Brunialti¹, José Medina-Pestana^{2,3}, Joe M. Butler⁴, Hessel Peters-6 Sengers^{4,5}, Lúcio Reguião-Moura^{2,3}, Reinaldo Salomão^{1*} 7 ¹ Division of Infectious Diseases, Escola Paulista de Medicina, Universidade Federal 8 de São Paulo, São Paulo 04023-900, Brazil; 9 ² Division of Nephrology, Escola Paulista de Medicina, Universidade Federal de São 10 Paulo, São Paulo 04038-031, Brazil; 11 ³ Hospital do Rim, Fundação Oswaldo Ramos, São Paulo 04038-002, Brazil; 12 ⁴ Center for Experimental and Molecular Medicine (CEMM), Amsterdam UMC, location 13 University of Amsterdam, Amsterdam, The Netherlands; 14 ⁵ Department of Epidemiology and Data Science, Amsterdam UMC, location Vrije 15 Universiteit, Amsterdam, the Netherlands; 16 17 18 * Correspondence: Giuseppe G. F. Leite and Reinaldo Salomão, Division of Infectious Diseases, Escola 19 Paulista de Medicina, Universidade Federal de São Paulo, São Paulo 04023-900, 20 Brazil. Email: giuseppe.gianini@unifesp.br and rsalomao@unifesp.br 21 22 23 24 25 26 27 28 29 30

Abstract

32

33

34

35

36

37

38 39

40

41 42

43

44

45

46

47

48 49

50

51 52

53

54

55

56

57 58

59

60

61

62

63

64

65

66

67

The emergence of the Coronavirus disease 2019 (COVID-19) pandemic in 2020 has profoundly impacted global health systems, particularly affecting vulnerable populations like kidney transplant recipients (KTRs). We prospectively collected blood samples from 17 PCR-confirmed COVID-19 KTR patients and 10 non-COVID-19 KTRs between May and September 2020. Using tandem mass tag-based quantitative proteomics, we characterized peripheral blood mononuclear cells (PBMCs) from KTRs alongside plasma protein biomarkers and lymphocyte counts, followed bioinformatics analyses. Our study revealed significant proteomic alterations within PBMCs of SARS-CoV-2 infected KTRs, particularly in pathways associated with glycolysis, glucose metabolism, and neutrophil degranulation. Additionally, we observed an altered immune response marked by elevated cytokines and inflammatory mediators, coupled with decreased lymphocyte counts. Notably, patients with acute kidney injury (AKI) exhibited worse outcomes, including higher rates of ICU transfer and mechanical ventilation. Comparison of PBMC proteomic profiles between AKI and non-AKI patients highlighted distinct immune-related pathways, with AKI patients showing pronounced alterations in innate immune responses, particularly in neutrophil degranulation. Moreover, our analysis unveiled a negative correlation between T cell counts and neutrophil degranulation, suggesting potential implications for immune dysregulation in COVID-19. Our findings shed light on the complex proteomic landscape and immune responses in COVID-19-infected KTRs, emphasizing the critical need for studies focused on this population, especially in individuals with AKI. Furthermore, our observations provide valuable insights for further exploration of therapeutic interventions targeting immune dysregulation pathways in this vulnerable population.

Keywords: KTRs, PBMC, acute kidney injury, SARS-CoV-2, systems biology, mass spectrometry

INTRODUCTION

68

69

70

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

The Coronavirus disease 2019 (COVID-19) pandemic, which emerged in 2020, rapidly became a global health crisis, profoundly affecting healthcare systems, economies, and overall quality of life [1, 2]. Prior to the achievement of widespread vaccination coverage, COVID-19 presented with a wide range of clinical manifestations, from asymptomatic or presymptomatic states to varying degrees of severity, including mild, moderate, severe, and, in some cases, life-threatening complications[3]. Individuals with compromised immune systems, especially those undergoing immunosuppressive therapy, were particularly vulnerable. Among these high-risk groups, kidney transplant recipients (KTRs) demonstrated notably higher case-fatality rates, even after vaccination [4, 5], and exhibited lower seroconversion rates following vaccination [6]. This elevated risk underscores the compounded vulnerabilities associated with immunosuppressive treatments and the presence of multiple comorbidities in these patients [7-9]. The cumulative number of comorbidities associated with an immune system impairment has led to diverse responses to COVID-19 among KTRs compared with non-transplanted patients [7-9]. Investigating a panel of circulating cytokines and vascular mediators in sequential samples, we previously demonstrated that both non-KTRs and KTRs infected with COVID-19 exhibited a similar transition from admission to convalescent samples. However, the key mediators differentiating patients from their respective controls (i.e., healthy volunteers and non-infected KTRs) were distinct. For non-KTRs, the top differentiators were inflammatory cytokines, whereas for KTRs, endothelial response patterns and levels of Neutrophil Gelatinase-Associated Lipocalin (NGAL)[10], an early marker of acute kidney injury (AKI), were the most

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

113

114

significant. AKI, commonly observed in numerous systemic conditions [11], has been linked to poor outcomes, a trend that persisted in COVID-19 patients. A multicenter study involving 1,680 KTRs with COVID-19 revealed that the mortality rate was 36.0% in those with AKI, compared to 19.1% in patients maintaining normal renal function, highlighting renal function as a key predictor of survival in this population [12]. Recently, mass spectrometry (MS)-based proteomics, primarily focused on plasma, serum, and urine, has emerged as a powerful tool to shed light on a broad spectrum of dysregulated biological processes in KTRs with COVID-19 [13, 14]. However, the influence of SARS-CoV-2 infection on peripheral blood mononuclear cells (PBMCs) in KTRs remains a subject of ongoing investigation. In this study, we employed a tandem mass tag (TMT)-based quantitative proteomic approach, coupled with bioinformatics analyses, to investigate altered proteins associated with dysregulated pathways and biological processes in kidney transplant recipients (KTRs) with COVID-19. We focused on patients with moderate to severe illness admitted to hospital wards who presented with or without acute kidney injury (AKI), as well as patients discharged from the hospital. Our aim was to provide insights into proteomic changes during the early stages of the disease and their association with AKI and post-clinical recovery. MATERIALS AND METHODS **Study Design and Population** This prospective cohort study was conducted at Hospital São Paulo, a tertiary university hospital in São Paulo, Brazil [15]. The study was approved by the research ethics committee (Process number 4.453.137), and all volunteers provided written

informed consent prior to enrolment. The study comprised adult patients (≥18 years old) diagnosed with COVID-19 based on positive reverse transcriptase polymerase chain reaction (RT-PCR) results from nasopharyngeal swabs. These patients were admitted to the hospital wards between May 10 and September 26, 2020. This period coincided with the first wave of the COVID-19 pandemic in Brazil (February 25, 2020, to November 5, 2020)[16], when the predominant variants observed were B.1.1.28 (20-30%) and B.1.1.33 (10-35%)[16]. Patients included in the cohort had moderate to severe illness, as defined by quidelines from the National Institutes of Health and the World Health Organization[17, 18]. Exclusion criteria encompassed patients referred to outpatient clinics or admitted directly to the ICU. Among the initial 68 COVID-19 patients in the cohort, 17 KTRs were selected for this study (for a comprehensive overview of the entire cohort, please refer to Peçanha-Pietrobom et al [15]). Additionally, a control group comprised 10 KTR volunteers without COVID-19 symptoms (KTR controls), matched to the patient group for time since transplantation, immunosuppressive therapy, sex, and age. None of the participants in this study were vaccinated due to the unavailability of vaccines at the time of enrolment. AKI was prospectively defined according to the Kidney Disease Improving Global Outcomes (KDIGO) criteria [19, 20]. Baseline graft function was assessed using creatinine levels recorded three months prior to COVID-19 diagnosis, and AKI was identified based on creatinine levels at hospital admission.

Sample Collection

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

136

137

138

Blood samples were collected from both patients and KTR controls into ethylenediaminetetraacetic acid (EDTA)-treated tubes (BD Biosciences, San Diego, CA, USA). Plasma and peripheral blood mononuclear cells (PBMCs) were separated

using a Ficoll gradient method (Ficoll-Paque PLUS, GE Healthcare Biosciences, Uppsala, Sweden). Plasma samples were stored at -80°C, and PBMCs were

preserved in liquid nitrogen for subsequent use.

Measurements

For detailed information on the proteomics experiments, data processing protocols,

plasma biomarker assays, and the corresponding analysis methods, please refer to

the supplementary methods in **Supplementary Material 1**.

Statistical Analysis

Statistical analyses were performed using R (version 4.3.0). Normality of data was assessed using the Shapiro–Wilk test and Quantile–Quantile (Q-Q) plots. Nonnormally distributed data were analyzed using the Mann–Whitney U test or the Kruskal–Wallis test, while normally distributed data were analyzed using Welch's t-test or analysis of variance (ANOVA). For post hoc testing of non-normally distributed data, Dunn's test of multiple comparisons using rank sums was employed; for normally distributed continuous data, Tukey's post hoc test was conducted. Categorical variables were compared using the chi-square test or Fisher's exact test, as appropriate. Biomarker data were log-transformed to normalize their distribution. To visualize the overall differences among plasma biomarkers, principal component analysis (PCA) was conducted following previously established method [21, 22]. Correlation analyses were performed using Spearman's rank correlation coefficient (Rho). Differences between groups were quantified using standardized mean differences (SMD) [23].

Bioinformatics

Differential protein abundance analysis was performed using the R/Bioconductor package limma. The model was adjusted for additional covariates: age, sex, time after transplantation (months), maintenance immunosuppressive therapy (class), and donor status (deceased or living). Differences in PBMC proteome profiling between the two groups were detected using the empirical Bayes moderated t-statistics, and Benjamini-Hochberg corrections were applied to all p-values to calculate the false discovery rates (FDR). Protein set enrichment analysis (PSEA) was performed using the fgsea package, with annotation information from the Reactome pathway database and hallmark gene sets from MSigDB. Additionally, single-sample PSEA (ssPSEA) was performed using the hacksig package and the Reactome pathway database. We focused on Reactome-defined immune-related pathways implicated in the host response to infection: innate immune system, adaptive immune system, cytokine signaling in the immune system, hemostasis, programmed cell death, and metabolism.

RESULTS

Clinical and Epidemiological Features of the Study Participants

Seventeen kidney transplant recipients (KTRs) with COVID-19, a subset of a hospital-admitted cohort with diverse clinical outcomes[15] were analyzed in this study (**Table 1**). According to the KDIGO criteria for staging AKI, we observed that six patients (35%) did not present with AKI (stage 0), while five (29%) were classified as stage 1, three (17%) as stage 2, and three (17%) as stage 3. The mean age was 54.0 years, and most were male (n = 10, 59%). The time between COVID-19 symptom onset and hospital admission was 7.5 ± 4.6 days. Primary symptoms included dyspnea (n = 12, 71%), cough (n = 12, 71%), fever (n = 7, 41%), diarrhea (n = 7, 41%), and

nausea/vomiting (n = 7, 41%). Arterial hypertension was the most prevalent comorbidity (n = 13, 76%). Additionally, 53% of patients required ICU admission, 41% underwent mechanical ventilation, 29% required renal replacement therapy, and 41% died. Among the survivors, six participated in a clinical follow-up at an average of 29.3 ± 5.0 days after hospital discharge (designated as Convalescent Sample 30 [CS30]). No significant differences were observed in demographic data, maintenance immunosuppressive therapy class, or donor status when comparing KTRs with COVID-19 and KTR controls (**Table 1**).

Global COVID-19 Perturbation of the PBMC Proteome, Plasma Proteins, and

Lymphocyte Counts in Kidney Transplant Recipients

A TMT--based quantitative proteomic approach combined with liquid chromatography-tandem mass spectrometry (LC-MS/MS) was employed to quantify differentially abundant proteins (DAPs) among KTRs. The cohort was categorized based on the timing of blood sampling: patients sampled during their hospital stay (D0-wards) and those sampled approximately 30 days after discharge (CS30). These groups were compared with KTRs non-COVID-19 (KTR controls). Across seven TMT batches, a total of 2,330 proteins were identified. Focusing on proteins quantified in at least 50% of samples reduced this number to 1,403 proteins, with an average of 1,242 proteins per sample (Supplementary Material 1: Supplementary Figure S1). Among these 1,403 proteins, 363 were differentially abundant between D0-wards and KTR controls (Supplementary Material 1: Supplementary Figure S2A and Supplementary Material 1), while 111 showed differential abundance between CS30 and KTR controls (Supplementary Material 1: Supplementary Figure S2B and Supplementary Material 3).

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

Reactome pathway enrichment analysis revealed that D0-wards patients exhibited alterations in 15 pathways compared with KTR controls, characterized by positive normalized enrichment scores (NES) in pathways associated with interferon response, innate immune system, and neutrophil degranulation. Conversely, pathways related to glycolysis and glucose metabolism exhibited negative NES. Similar NES patterns were observed in hallmark gene set enrichment analysis, with positive NES in pathways related to interferon response and inflammatory processes, and negative NES in metabolism-related pathways (Figure 1A). Notably, only metabolism-related pathways remained altered in CS30 patients (Figure 1A). Plasma biomarker levels indicative of cytokine/inflammation and endothelial cell activation were significantly elevated in D0-wards patients (Figure 1B, and Supplementary Material 1: Supplementary Figure S2). Additionally, two proteins, NGAL and myeloperoxidase (MPO), were identified in both plasma and PBMCs (proteomics), demonstrating a positive moderate correlation (Figure 1C). Furthermore, the absolute number of lymphocytes, specifically T lymphocytes (CD3⁺CD45⁺), T cytotoxic (CD3⁺CD8⁺), and T helper (CD3⁺CD4⁺) were lower in D0wards compared to KTR controls (Figure 1D). In contrast to admission samples, all plasma biomarkers (Supplementary Material 1: Supplementary Table S1) and absolute lymphocyte counts were comparable between CS30 and KTR controls (Supplementary Material 1: Supplementary Table S2), suggesting a potential return to a homeostatic state approximately 30 days after hospital discharge. Host response associated with acute kidney injury in KTR COVID-19 patients We compared KTR COVID-19 patients who presented with AKI (N=6) to those who did not (N=11) during ward admission. Patients with AKI presented with higher

235

236

237

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

Sequential Organ Failure Assessment (SOFA) scores (SMD: 0.90), increased C-Reactive Protein (CRP) levels (SMD: 0.60), and elevated creatinine levels (SMD: 1.40) upon ward admission. The AKI group experienced worse outcomes, including a higher rate of ICU transfers (SMD: 0.64), increased need for mechanical ventilation (SMD: 0.86), and greater hospital mortality (SMD: 0.86). Interestingly, creatinine showed a strong positive correlation with CRP (Rho=0.50, p<0.05) and SOFA respiratory subscores (Rho=0.68, p=0.002) (Supplementary Material 1: Supplementary Figure **S4**). We compared the PBMC proteomic alterations in AKI and non-AKI COVID-19 patients using ssPSEA for Reactome-defined immune-related pathways. Our analysis revealed alterations in seven innate immune-related pathways, three adaptive immune system pathways, and five cytokine signaling pathways in the immune system. Additionally, no alterations were observed in hemostasis, while four metabolic pathways and one programmed cell death pathway showed alterations (Figure 2A). Indeed, the innate immune-related pathways exhibited the most differences when comparing patients with AKI and non-AKI; these pathways also demonstrated a pattern of positive correlation with creatinine, SOFA, and CRP levels (Figure 2B). Next, we explored the differences between KTR COVID-19 patients with AKI and non-AKI based on 15 host response biomarkers reflective of two key pathophysiological domains (cytokine/inflammatory response and endothelial cell activation/procoagulant responses) in plasma obtained on admission to the wards. First, we generated domain-specific PCA plots to compare the groups (Figure 3). There were significant differences in plasma biomarkers grouped in the cytokine/inflammatory response domain between patients with AKI and non-AKI. We also identified a substantial

259

260

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

overlap in the endothelial cell activation/procoagulant responses between the AKI and non-AKI groups (Figure 3A). The complete contribution of each biomarker to a principal component (PC) score is depicted in Supplementary Material 1: Supplementary Table S3. When comparing the magnitude of individual biomarker differences expressed as Hedges' g, we observed moderate to large increases in cytokine/inflammatory markers among AKI patients, while endothelial cell activation/procoagulant markers showed small or negligible differences (Figure 3B). Subsequently, we evaluated the absolute number of total lymphocytes, which showed statistical differences when comparing the KTR control and COVID-19 AKI groups (Figure 3C). We also observed differences between the control and COVID-19 AKI groups for T helper cells. For T lymphocytes and T cytotoxic cells, differences were found in both comparisons between the KTR control vs. COVID-19 AKI groups, as well as between the KTR control vs. non-AKI groups. No differences were found in the comparison between the groups for the helper/cytotoxic ratio, B lymphocytes, and NK cells. Interestingly, for total lymphocytes, T lymphocytes, T cytotoxic cells, and T helper cells, the AKI group consistently showed lower absolute values than the non-AKI group, but with no statistical difference in the pairwise comparison. Previous studies suggest an increase in immature cells, such as low-density neutrophils (LDNs) or granulocytic/polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs), in COVID-19 patients, which correlate with T cell suppression [24, 25]. LDNs commonly co-purify with PBMCs in various infections, enriching pathways like "neutrophil degranulation" in omics studies [26-31]. Therefore, we tested the correlation between the absolute values of T lymphocytes and the "neutrophil degranulation" ssPSEA scores, which showed a moderate negative correlation between T lymphocytes (Rho=-0.43, p=0.02), T helper cells (Rho=-0.45, p=0.03), and the "neutrophil degranulation" score (**Supplementary Material 1**: **Supplementary Figure S5**). A weak negative and not statistically significant correlation was found between T cytotoxic cells and the "neutrophil degranulation" score (Rho=-0.35, p=0.08).

DISCUSSION

In this study, we investigated KTRs infected with SARS-CoV-2 during the initial wave of the COVID-19 pandemic in São Paulo, Brazil. Based on the reported increased severity of COVID-19 in KTRs [4, 5, 7-9], we aimed to investigate the changes in proteomics within PBMCs in this specific population. Additionally, we explored the reported immune dysregulation and endothelial cell activation/procoagulant alterations in COVID-19 [10, 32, 33], particularly emphasizing the early stages of hospitalization while patients are in the ward. Furthermore, we investigated the reported reductions in absolute counts of lymphocytes, especially T lymphocytes and their subsets, during the acute phase of COVID-19 [34, 35], with a specific focus on KTRs.

The proteomic response during the acute phase of COVID-19 has been widely explored [28, 30, 31, 36], while the proteomic alterations within PBMCs of KTRs were negligible. Our study revealed proteomic alterations linked to inflammatory/immune response pathways, indicated by positive NES. Interestingly, the majority of these pathways reverted to a status similar to that of non-COVID-19 KTRs after 30 days. This pattern aligns with our previous findings from a separate cohort of COVID-19 patients without KTRs [28] and is consistent with other omics reports [25, 30, 31]. Notably, the glycolysis and glucose metabolism pathways exhibited a negative NES

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

and remained altered after 30 days. This metabolic alteration may affect immune cell function in pathogen recognition, as glycolysis plays a pivotal role in this process [37]. This dysfunctional glycolysis profile shares similarities with findings from proteomic studies of PBMCs from critically ill COVID-19 patients [28], transcriptomic/metabolic profiling of CD14+ monocytes from patients with moderate COVID-19 [38], and singlecell RNA sequencing in monocytes and macrophages from severe patients with COVID-19-associated pulmonary aspergillosis [39]. The impaired glycolysis observed in this context may serve as an indicator of the dysfunctional host response, potentially contributing to heightened morbidity and mortality rates among KTRs. Next, we investigated the proteomic alterations based on the presence of AKI, a prevalent condition in systemic illnesses affecting a significant portion of hospitalized COVID-19 patients [40]. Analysis of immune-related pathways revealed increased NES in the innate immune system, complement cascade, regulated necrosis, antimicrobial peptides, and neutrophil degranulation in COVID-19 AKI patients. These results are in line with studies discussing the pathophysiology of COVID-19associated AKI, which is believed to be multifaceted [40], involving factors such as local and systemic inflammatory/immune response, and activation of coagulation cascades [41, 42]. This is further evidenced when examining host response biomarkers, where the PCA corresponding to this cytokine/inflammatory response

domain clearly separates patients with AKI from those without, a distinction not

observed in the endothelial domain. It is noteworthy that COVID-19 pathophysiology

in KTRs remains largely unknown. While various general factors commonly

encountered in critically ill patients, including mechanical ventilation, hypoxia,

hypotension, and exposure to nephrotoxic agents, are recognized contributors to

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

kidney injury, [41] the role of direct viral infection with renal tropism, as proposed by some studies, remains unclear [43, 44]. Although no statistically significant differences were observed in lymphocyte counts between the AKI and non-AKI groups, it is likely that these disturbances were more severe in the AKI group, as illustrated by the finding that absolute counts of total lymphocytes and T helper cells were lower in the AKI group but not in the non-Aki group compared to the controls. Previous studies have demonstrated that T lymphocyte counts and their subsets typically decrease during the acute phase of COVID-19,[34, 35, 45]. T lymphocytes play a pivotal role in clearing the virus during SARS-CoV infection [46, 47]. Interestingly, the increase in LDNs/PMN-MDSCs may directly correlate with the decrease in the number of T cells [24, 25]. Despite their immunosuppressive properties, LDNs/PMN-MDSCs have also been associated with a pro-inflammatory phenotype, characterized by elevated levels of cytokine secretion and formation of neutrophil extracellular traps [27, 48, 49]. The presence of LDNs has been observed in previous studies [26, 28, 29], and might be correlated to the severity of infectious diseases [25, 30]. In fact, the AKI group is more severe than the non-AKI, showing higher SOFA scores, CRP levels, and worse outcomes. This may be associated with high scores for LDNs, as well as inflammatory/immune responses. Our findings suggest a relationship between T-cell suppression and elevated levels of LDN-related proteins in PBMCs during COVID-19, particularly in patients with AKI. This association may carry important therapeutic implications for managing immune dysregulation in KTRs, highlighting the need for targeted interventions aimed at mitigating these immune alterations. This study has some limitations. First, the sample size was relatively small, and all patients were enrolled at a single center. Additionally, the absence of a validation

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

cohort from another hospital in a different geographical region limits the generalizability of our findings. Moreover, we did not investigate the influence of viral load or the roles of virus variants on the results obtained. Our study was conducted in 2020, so the relevance to current variants is less clear, since SARS-CoV2 variants exhibit increasing fitness, and declining pathogenicity and induced-inflammatory response [50]. Furthermore, functional assays to validate glycolysis metabolism changes and/or the potential contribution of LDNs in AKI were not conducted, which could have provided further insight into our results. Despite these limitations, our study also has notable strengths. We investigated PBMCs, a cell type that is not often explored in COVID-19 proteomics research. Our study of KTRs infected with SARS-CoV-2, along with a well-established cohort of controls, provides valuable insights and is relatively unexplored. Additionally, all individuals were unvaccinated, allowing for a clearer assessment of proteomic alterations in the absence of vaccination. Furthermore, the samples obtained in the wards and after discharge provided a comprehensive understanding of cellular proteomic changes throughout the initial symptoms of the disease and convalescence. Future studies with larger, more diverse cohorts are needed to validate our findings and evaluate their long-term clinical implications. As a next step, we aim to explore patients with community-acquired infections, including both KTRs and non KTRs, to investigate broader mechanisms of immune dysregulation. These insights lay the groundwork for the development of targeted therapeutic interventions to address immune dysregulation in vulnerable populations, particularly kidney transplant recipients. In summary, our study offers preliminary insights into the proteomic alterations within PBMCs of KTRs infected with SARS-CoV-2 during the early phase of the COVID-19

pandemic. We identified significant dysregulation in key biological pathways, particularly those involved in glycolysis, glucose metabolism, and neutrophil degranulation, which may reflect the heightened inflammatory state associated with COVID-19 in this vulnerable population. While our findings suggest an altered immune response—characterized by elevated cytokines, inflammatory mediators, and decreased lymphocyte counts—these results must be interpreted cautiously due to the small sample size. The observed association between T-cell suppression and increased levels of LDN-related proteins in AKI patients warrants further investigation, as it may hold therapeutic implications for mitigating immune dysregulation in COVID-19-infected KTRs.

Data Availability Statement

- Raw and processed mass spectrometry proteomic data generated in this study are
- available at ProteomeXchange with the dataset identifier PXD051702.

Author Contributions

- 394 Giuseppe G. F. Leite (Conceptualization; Proteomic sample preparation; Data
- curation; Formal analysis; Investigation; Methodology; Visualization; Writing original
- 396 draft; Writing review & editing);
- Mônica Bragança Sousa (Involved in collecting the data; Writing review & editing);
- Larissa de Oliveira C. P. Rodrigues (Involved in collecting the data; Writing review &
- 399 editing);

380

381

382

383

384

385

386

387

388

389

390

- 400 Milena Karina Colo Brunialti (Involved in collecting the data; Writing review & editing);
- José Medina-Pestana Writing (Intellectual input; Writing review & editing);
- Joe M. Butler Writing (Methodology; Intellectual input; Writing review & editing);
- Hessel Peters-Sengers (Methodology; Intellectual input; Writing review & editing);
- Lúcio Requião-Moura (Supervision Intellectual input; Data curation; Writing original
- 405 draft; Writing review & editing);
- Reinaldo Salomão (Funding acquisition; Supervision Intellectual input; Data curation;
- 407 Visualization; Writing original draft; Writing review & editing)

408 409 **Funding** 410 This work was funded by FAPESP (Grants 2017/21052-0 and 2020/05110-2) to R.S. 411 G.G.F.L. has a scholarship from FAPESP (2019/20532-3). 412 **Conflict of Interest** 413 The authors declare that the research was conducted in the absence of any 414 commercial or financial relationships that could be construed as a potential conflict of 415 interest. 416 **Acknowledgments** 417 The authors thank Nancy Bellei, Universidade Federal de São Paulo, for the SARS-418 CoV-2 PCR test; Paulo R. Abrão Ferreira, Jaquelina Sonoe Ota-Arakaki and Paula M. 419 Peçanha-Pietrobom for the support with the selection and enrollment of patients. We 420 thank Paolo Di Mascio and Graziella E. Ronsein for the mass spectrometry analyses 421 performed at the Redox Proteomics Core of the Mass Spectrometry Resource at 422 423 Chemistry Institute, University of São Paulo (FAPESP grant numbers 2012/12663-1 and 2016/00696-3, CEPID Redoxoma 2013/07937-8). 424 Supplementary material 425 Supplementary material 1. Methods, Tables, and Figures. 426 Supplementary material 2. List of differentially abundant proteins in between D0-427 wards and KTR controls 428 Supplementary material 3. List of differentially abundant proteins in CS30 and KTR 429 controls 430 431 432

REFERENCES

- 1. Naseer S, Khalid S, Parveen S, Abbass K, Song H, Achim MV. COVID-19 outbreak: Impact on global economy. *Front Public Health*. 2022; **10**: 1009393.
- Squires N, Garfield R, Mohamed-Ahmed O, et al. Essential public health functions: the key to resilient health systems. *BMJ Glob Health*. 2023; **8**.
- Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features,
 Evaluation, and Treatment of Coronavirus (COVID-19). StatPearls Publishing,
 Treasure Island (FL), 2022.
- 441 4. Weiss A, Hendrickx R, Stensgaard E, Jellingsø M, Sommer MOA. Kidney
 442 Transplant and Dialysis Patients Remain at Increased Risk for Succumbing to
 443 COVID-19. *Transplantation*. 2023; **107**: 1136-8.
- Demir E, Ucar ZA, Dheir H, et al. COVID-19 in Kidney Transplant Recipients: A Multicenter Experience from the First Two Waves of Pandemic. *BMC Nephrology*. 2022; **23**: 183.
- 447 6. Sanders JF, Messchendorp AL, de Vries RD, et al. Antibody and T-Cell 448 Responses 6 Months After Coronavirus Disease 2019 Messenger RNA-1273 449 Vaccination in Patients With Chronic Kidney Disease, on Dialysis, or Living With 450 a Kidney Transplant. *Clin Infect Dis.* 2023; **76**: e188-e99.
- 451 7. Medina-Pestana J, Cristelli MP, Foresto RD, Tedesco-Silva H, Requião-Moura 452 LR. The Higher COVID-19 Fatality Rate Among Kidney Transplant Recipients 453 Calls for Further Action. *Transplantation*. 2022; **106**: 908-10.
- 454 8. Callaghan CJ, Mumford L, Curtis RMK, et al. Real-world Effectiveness of the 455 Pfizer-BioNTech BNT162b2 and Oxford-AstraZeneca ChAdOx1-S Vaccines 456 Against SARS-CoV-2 in Solid Organ and Islet Transplant Recipients. 457 *Transplantation*. 2022; **106**: 436-46.
- 458 9. Choudhary D, Kenwar D, Sharma A, et al. Risk factors for mortality in kidney 459 transplant recipients with COVID-19: a single centre experience and case— 460 control study. *BMC Nephrology*. 2022; **23**: 241.
- Human Harden Har
- Devarajan P. Neutrophil gelatinase-associated lipocalin: a promising biomarker for human acute kidney injury. *Biomark Med*. 2010; **4**: 265-80.
- Requião-Moura LR, Sandes-Freitas TV, Viana LA, et al. High mortality among kidney transplant recipients diagnosed with coronavirus disease 2019: Results from the Brazilian multicenter cohort study. *PLoS One*. 2021; **16**: e0254822.
- 470 13. Gisby J, Clarke CL, Medjeral-Thomas N, et al. Longitudinal proteomic profiling of dialysis patients with COVID-19 reveals markers of severity and predictors of death. *Elife*. 2021; **10**.

- Lin H, Ma X, Xiao F, et al. Identification of a special cell type as a determinant of the kidney tropism of SARS-CoV-2. *The FEBS Journal*. 2021; **288**: 5163-78.
- Peçanha-Pietrobom PM, Leite GGF, Hunter J, et al. The clinical course of hospitalized moderately ill COVID-19 patients is mirrored by routine hematologic tests and influenced by renal transplantation. *PLOS ONE*. 2021; **16**: e0258987.
- 479 16. Zeiser FA, Donida B, da Costa CA, et al. First and second COVID-19 waves in 480 Brazil: A cross-sectional study of patients' characteristics related to 481 hospitalization and in-hospital mortality. *The Lancet Regional Health* – 482 *Americas*. 2022; **6**.
- 17. National Institutes of Health. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. https://www.covid19treatmentguidelines.nih.gov/. [Accessed Dezember 15, 2022].
- 487 18. World Health Organization. Clinical management of COVID-19: living guideline, 488 15 September 2022. 2022. https://iris.who.int/handle/10665/362783. 489 [Accessed Dezember 15, 2022].
- 490 19. KDIGO AKI Work Group. KDIGO Clinical Practice Guideline for Acute Kidney 491 Injury. *Kidney Int Suppl.* 2012; **2**: 1-141.
- Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative w. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Critical care*. 2004; **8**: R204-12.
- 497 21. Michels EHA, Appelman B, Brabander Jd, et al. Age-related changes in plasma 498 biomarkers and their association with mortality in COVID-19. *European* 499 *Respiratory Journal*. 2023: 2300011.
- Peters-Sengers H, Butler JM, Uhel F, et al. Source-specific host response and outcomes in critically ill patients with sepsis: a prospective cohort study. *Intensive Care Med.* 2022; **48**: 92-102.
- 503 23. Lin L, Aloe AM. Evaluation of various estimators for standardized mean difference in meta-analysis. *Stat Med*. 2021; **40**: 403-26.
- Morrissey SM, Geller AE, Hu X, et al. A specific low-density neutrophil population correlates with hypercoagulation and disease severity in hospitalized COVID-19 patients. *JCI Insight*. 2021; **6**.
- 508 25. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms of COVID-19 in a deeply phenotyped young patient cohort. *Sci Transl Med*. 510 2022; **14**: eabj7521.
- Leite GGF, Ferreira BL, Tashima AK, et al. Combined Transcriptome and Proteome Leukocyte's Profiling Reveals Up-Regulated Module of Genes/Proteins Related to Low Density Neutrophils and Impaired Transcription and Translation Processes in Clinical Sepsis. *Front Immunol.* 2021; **12**.

- 515 27. Eisfeld AJ, Halfmann PJ, Wendler JP, et al. Multi-platform 'Omics Analysis of Human Ebola Virus Disease Pathogenesis. *Cell Host Microbe*. 2017; **22**: 817-517 29.e8.
- Leite GGF, Brunialti MKC, Peçanha-Pietrobom PM, et al. Understanding COVID-19 progression with longitudinal peripheral blood mononuclear cell proteomics: Changes in the cellular proteome over time. *iScience*. 2023; **26**: 107824.
- 522 29. Carapito R, Li R, Helms J, et al. Identification of driver genes for critical forms 523 of COVID-19 in a deeply phenotyped young patient cohort. *Science* 524 *Translational Medicine*. 2022; **14**: eabj7521.
- 525 30. Potts M, Fletcher-Etherington A, Nightingale K, et al. Proteomic analysis of circulating immune cells identifies cellular phenotypes associated with COVID-19 severity. *Cell Rep.* 2023; **42**: 112613.
- 528 31. Li J, Guo M, Tian X, et al. Virus-Host Interactome and Proteomic Survey Reveal 529 Potential Virulence Factors Influencing SARS-CoV-2 Pathogenesis. *Med (N Y)*. 530 2021; **2**: 99-112.e7.
- 531 32. Cron RQ, Caricchio R, Chatham WW. Calming the cytokine storm in COVID-532 19. *Nat Med*. 2021; **27**: 1674-5.
- 533 33. Sims JT, Krishnan V, Chang CY, et al. Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. *J Allergy Clin Immunol*. 2021; **147**: 107-11.
- 536 34. Cantenys-Molina S, Fernández-Cruz E, Francos P, Lopez Bernaldo de Quirós JC, Muñoz P, Gil-Herrera J. Lymphocyte subsets early predict mortality in a large series of hospitalized COVID-19 patients in Spain. *Clinical and Experimental Immunology*. 2020; **203**: 424-32.
- Huang M, Wang Y, Ye J, Da H, Fang S, Chen L. Dynamic changes of Tlymphocyte subsets and the correlations with 89 patients with coronavirus disease 2019 (COVID-19). *Ann Transl Med*. 2020; **8**: 1145.
- 543 36. Gu X, Wang S, Zhang W, et al. Probing long COVID through a proteomic lens: a comprehensive two-year longitudinal cohort study of hospitalised survivors. *eBioMedicine*. 2023; **98**.
- Kelly B, O'Neill LA. Metabolic reprogramming in macrophages and dendritic cells in innate immunity. *Cell Res.* 2015; **25**: 771-84.
- 548 38. Maher AK, Burnham KL, Jones EM, et al. Transcriptional reprogramming from innate immune functions to a pro-thrombotic signature by monocytes in COVID-19. *Nat Commun*. 2022; **13**: 7947.
- Feys S, Vanmassenhove S, Kraisin S, et al. Lower respiratory tract single-cell RNA sequencing and neutrophil extracellular trap profiling of COVID-19-associated pulmonary aspergillosis: a single centre, retrospective, observational study. *Lancet Microbe*. 2024; **5**: e247-e60.
- Nugent J, Aklilu A, Yamamoto Y, et al. Assessment of Acute Kidney Injury and Longitudinal Kidney Function After Hospital Discharge Among Patients With and Without COVID-19. *JAMA Netw Open*. 2021; **4**: e211095.

- Legrand M, Bell S, Forni L, et al. Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol*. 2021; **17**: 751-64.
- 560 42. Wu H, Larsen CP, Hernandez-Arroyo CF, et al. AKI and Collapsing 561 Glomerulopathy Associated with COVID-19 and APOL 1 High-Risk Genotype. 562 *J Am Soc Nephrol*. 2020; **31**: 1688-95.
- 563 43. Miller SE, Brealey JK. Visualization of putative coronavirus in kidney. *Kidney Int.* 2020; **98**: 231-2.
- Delorey TM, Ziegler CGK, Heimberg G, et al. COVID-19 tissue atlases reveal SARS-CoV-2 pathology and cellular targets. *Nature*. 2021; **595**: 107-13.
- Iannetta M, Buccisano F, Fraboni D, et al. Baseline T-lymphocyte subset absolute counts can predict both outcome and severity in SARS-CoV-2 infected patients: a single center study. *Scientific Reports*. 2021; **11**: 12762.
- 570 46. Zhao J, Zhao J, Van Rooijen N, Perlman S. Evasion by stealth: inefficient immune activation underlies poor T cell response and severe disease in SARS572 CoV-infected mice. *PLoS Pathog.* 2009; **5**: e1000636.
- 573 47. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019 (COVID-19) in Wuhan, China. *Clin Infect Dis.* 2020; **71**: 762-575 8.
- 576 48. Silvestre-Roig C, Fridlender ZG, Glogauer M, Scapini P. Neutrophil Diversity in Health and Disease. *Trends Immunol*. 2019; **40**: 565-83.
- 578 49. Carmona-Rivera C, Kaplan MJ. Low-density granulocytes: a distinct class of neutrophils in systemic autoimmunity. *Semin Immunopathol*. 2013; **35**: 455-63.
- 580 50. Barh D, Tiwari S, Rodrigues Gomes LG, et al. SARS-CoV-2 Variants Show a Gradual Declining Pathogenicity and Pro-Inflammatory Cytokine Stimulation, an Increasing Antigenic and Anti-Inflammatory Cytokine Induction, and Rising Structural Protein Instability: A Minimal Number Genome-Based Approach. *Inflammation*. 2023; **46**: 297-312.

585

586

587

588

589

590

591

592

Tables

Table 1. Baseline characteristics and clinical outcomes of KTR COVID-19 patients at ward admission and KTR Controls

	D0-Wards , (N=17) ¹	KTR Controls, (N=10) ¹	<i>p</i> -value
Demographics			
Age years	54.1 (11.1)	55.1 (6.3)	0.91
Male sex	10 (59%)	6 (60%)	0.96
Time after transplantation (months)	89.6 (90.6)	118.2 (119.4)	0.72
BMI	25.6 (4.1)		
Admission type, wards	17 (100%)		
Maintenance immunosuppressi	ve therapy (class)		0.09
Aza/MPA+Pred	2 (12%)	0 (0%)	
CNI+Aza/MPA+Pred	15 (88%)	8 (80%)	
CNI+mTORi+Pred	0 (0%)	2 (20%)	
Donor information	, ,	,	>0.99
Deceased donor	12 (71%)	7 (70%)	
Living donor	5 (29%)	3 (30%)	
AKI stages (KDIGO criteria)			
0	6 (35%)		
1	5 (29%)		
2	3 (17%)		
3	3 (17%)		
Comorbidity	· ,		
Charlson Index	3.9 (1.5)		
Renal Disease Moderate or Severe	17 (100%)		
Diabetes	6 (35%)		
Hypertension	13 (76%)		
Obesity	1 (5.9%)		
Disease severity on admission			
SOFA score	2.9 (1.8)		
Temperature °C	36.8 (0.9)		
Heart rate	85.6 (13.4)		
Respiratory rate	23.2 (3.7)		
Saturation O2	92.9 (3.2)		
Respiratory support			
No	10 (59%)		
Non-rebreather masks	2 (12%)		

Complemental consens	F (20%)	
Supplemental oxygen	5 (29%)	
Symptoms on admission		
Symptoms to wards (days)	7.5 (4.6)	
Fever	7 (41%)	
Cough	12 (71%)	
Myalgia	6 (35%)	
Fatigue/Anxiety	2 (12%)	
Dyspnea	12 (71%)	
Headache	4 (24%)	
Nausea/Vomiting	7 (41%)	
Anosmia	3 (18%)	
Dysgeusia	3 (18%)	
Diarrhea	7 (41%)	
Laboratory on admission		
Hemoglobin, g/dL	12.3 (1.5)	
Hematocrit (%)	37.6 (3.9)	
Red Cell Distribution Width, (%)	13.9 (1.4)	
Neutrophils, cells/µl	5,120.1 (2,128.5)	
Lymphocytes, cells/µl	765.2 (456.3)	
Monocytes, cells/μl	392.6 (263.9)	
Platelets, cells/µl	196,705.9	
	(69,058.6)	
Creatinine, mg/dL	2.1 (1.4)	
C-Reactive Protein, mg/L	103.2 (50.7)	
D-dimer, μg/mL FEU	1.2 (0.7)	
Outcomes		
Transferred to ICU	9 (53%)	
Mechanical ventilation	7 (41%)	
Renal replacement therapy	5 (29%)	
Days in ICU	19.6 (13.3)	
Death in ICU (30-day mortality)	7 (41%)	

¹Continuous variables are shown as mean ± SD. Categorical variables are shown as absolute numbers (percentages). Abbreviation: Aza = azathioprine, CNI = Calcineurin inhibitors, MPS = mycophenolate acid, Pred = prednisone, mTORi = mammalian target of rapamycin inhibitors.

Table 2. Demography, comorbidities, clinical and laboratory admission data, and outcomes stratified according to the presence of acute kidney injury

Characteristic	AKI (N=11) ¹	non-AKI (N=6) ¹	SMD
Demographics			
Age years	51.7 (12.4)	58.2 (7.4)	-0.56
Male sex	7 (64%)	3 (50%)	0.13
BMI	24.8 (4.4)	26.9 (3.7)	-0.53
Comorbidity			
Charlson Index	3.8 (1.7)	4.0 (1.4)	-0.12
Diabetes	3 (27%)	3 (50%)	-0.48
Hypertension	7 (64%)	6 (100%)	-1.07
Obesity	0 (0%)	1 (17%)	-0.63
Disease severity on admis	sion		
SOFA score	3.5 (1.8)	2.0 (1.4)	0.90
Temperature °C	36.9 (1.0)	36.6 (0.6)	0.42
Heart rate	83.8 (15.1)	88.8 (9.9)	-0.39
Respiratory rate	22.9 (4.6)	23.8 (1.3)	0.27
Saturation O2	92.8 (3.6)	93.0 (2.5)	-0.06
Respiratory support	4 (36.4%)	3 (50.0%)	0.28
Symptoms on admission			
Symptoms to wards (days)	8.1 (5.5)	6.5 (2.1)	0.38
Fever	5 (45%)	2 (33%)	0.25
Cough	7 (64%)	5 (83%)	-0.46
Myalgia	5 (45%)	1 (17%)	0.66
Fatigue/Anxiety	1 (9.1%)	1 (17%)	-0.23
Dyspnea	7 (64%)	5 (83%)	0.46
Headache	2 (18%)	2 (33%)	0.35
Vomiting/nausea	4 (36%)	3 (50%)	0.28
Anosmia	1 (9.1%)	2 (33%)	0.62
Dysgeusia	1 (9.1%)	2 (33%)	0.62
Diarrhea	4 (36%)	3 (50%)	0.28
Laboratory on admission			
Hemoglobin, g/dL	12.1 (1.5)	12.8 (1.4)	-0.46
Hematocrit (%)	37.1 (4.0)	38.7 (3.9)	-0.40
RDW, (%)	14.0 (1.7)	13.6 (0.8)	0.35
Neutrophils, cells/µl	4,846.5 (1,646.6)	5,621.5 (2,934.0)	-0.33
Lymphocytes, cells/µl	677.3 (448.4)	926.5 (464.8)	-0.55
Monocytes, cells/µl	393.8 (295.1)	390.3 (220.7)	0.01
Platelets, cells/μl	206,090.9 (75,525.4)	179,500.0 (57,479.6)	0.40

Creatinine, mg/dL	2.6 (1.5)	1.2 (0.3)	1.40
C-Reactive Protein, mg/L	112.4 (46.6)	86.4 (57.9)	0.60
D-dimer, μg/mL FEU	1.3 (0.7)	1.1 (0.9)	0.23
Outcomes			
Transferred to ICU	7 (64%)	2 (33%)	0.64
Mechanical ventilation	6 (55%)	1 (17%)	0.86
Renal replacement therapy	3 (27.3%)	2 (33.3%)	-0.13
Days in ICU	22.1 (13.3)	10.5 (12.0)	0.92
Hospital mortality	6 (55%)	1 (17%)	0.86

¹Continuous variables are shown as mean ± SD. Categorical variables are shown as absolute numbers (percentages). SMD: standardized mean differences.

Figure legends

Figure 1. Comprehensive assessment of COVID-19 impact on PBMC proteome, plasma proteins, and lymphocyte counts.

Description Figure 1: A) Protein set enrichment analysis (PSEA) demonstrating protein perturbations in D0-wards patients (n=17) versus KTR controls (n=10), and CS30 patients (n=6) versus KTR controls. Circle size represents the -log10(BH-adjusted p-value), while color denotes the normalized enrichment score (NES). Red indicates increased NES, and blue indicates decreased NES. B) Heatmap showing the magnitude of biomarker differences between D0-wards patients and KTR controls, quantified using Hedges' g. The red gradient highlights elevated biomarker levels in D0-wards patients. (For pairwise comparisons, see Figure S3). C) Scatter plot illustrating Spearman's rank correlation coefficients (Rho) between myeloperoxidase (MPO) and neutrophil gelatinase-associated lipocalin (NGAL) abundances in plasma and PBMCs (proteomic data). P-values are BH-adjusted, and D) Box plot comparing absolute lymphocyte counts between D0-wards COVID-19 patients and KTR controls. Statistical analyses were performed using Welch's t-test, with significance levels indicated by **p ≤ 0.01 and ***p ≤ 0.001.

Figure 2. Alterations in immune-related pathways in COVID-19 patients stratified according to the presence of acute kidney injury.

Description Figure 2: A) Single-sample protein set enrichment analysis (ssPSEA) was performed on D0-wards COVID-19 patients stratified by the presence of acute kidney injury (AKI, n=11) and non-AKI (n=6), as well as KTR controls (n=10). The figure presents only immune-related pathways that showed significant differences between the groups. Statistical analyses were conducted using ANOVA with Tukey's post-hoc test, corrected by the Benjamini-Hochberg method. Significance is indicated as follows: *p \leq 0.05, **p \leq 0.01, ***p \leq 0.001, and ****p \leq 0.0001, and **B**) Heatmap showing Spearman's rank correlation coefficients (Rho) between the sequential organ failure assessment (SOFA) score, C-reactive protein (CRP) levels, creatinine levels, and ssPSEA pathway scores in D0-wards COVID-19 patients (n=17). Abbreviations: TLR cascades: Toll-like receptor cascades, NLR signaling: Nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway, TCR signaling: T cell receptor signaling, Immunoregulatory between Lymphoid & non-Lymphoid cell: Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell, Rap1 signaling: Ras-proximate-1 signaling and Metabolism of vit and cofactors: Metabolism of vitamins and cofactors.

675

676

677

678

679

680

681

682

683

684

685

686

687

688

689

690

691

692

693

694

695

696

697

698

699

700

Figure 3. Host response biomarkers and lymphocyte count alterations in COVID-19 patients stratified according to the presence of acute kidney injury

Description Figure 3: A) Principal component analysis of cytokine/inflammatory responses and endothelial cell activation/procoagulant responses. The X-axis label shows the percentage of explained variance on principal component 1, while the Yaxis label shows the percentage of explained variance on principal component 2. The ellipse indicates the central 25% of the groups. The arrows indicate the direction (arrow orientation) and strength (arrow length) of the correlation between each biomarker and the PCs. The complete contribution of each biomarker to a PC score is depicted in Supplementary Table S3. B) Heatmap representing the Hedges' g effect size between the AKI COVID-19 group compared with the non-AKI group (for pairwise comparison see Supplementary Table S4), and C) Box plot illustrating differences in lymphocyte absolute counts between D0-wards COVID-19 patients stratified according to the presence of acute kidney injury (AKI, n=11, and non-AKI, n=06) and KTR controls (n=10). Statistical analyses were performed using the ANOVA test with Tukey posthoc test corrected by the Benjamini-Hochberg method. * Tukey post-hoc test p ≤ 0.05 and ** p ≤ 0.01. Abbreviations: IL: interleukin, GDF: growth/differentiation factor, G-CSF: granulocyte-colony stimulating factor, IFN: interferon, CRP: C-Reactive Protein, NGAL: neutrophil gelatinase-associated lipocalin, MPO: Myeloperoxidase, ADAMTS-13: ADAM metallopeptidase with thrombospondin type 1 motif 13, sP-selectin: Soluble platelet selectin, sVCAM-1: Serum vascular cell adhesion molecule-1 and sICAM-1: Soluble Intercellular Adhesion Molecule-1.





